

Correction

Article title: Canadian Thoracic Society 2021 Guideline update: Diagnosis and management of asthma in preschoolers, children and adults

Authors: Connie L. Yang, Elizabeth Anne Hicks, Patrick Mitchell, Joe Reisman, Delanya Podgere, Kathleen M. Hayward, Mark Waite and Clare D. Ramsey

Journal: Canadian Journal of Respiratory, Critical Care, and Sleep Medicine


Bibliometrics: Volume 5, Number 6, pages 348–361

DOI: <http://dx.doi.org/10.1080/24745332.2021.1945887>

In the online publication of the above article, Figure 3 appeared incorrectly.

In the patient with well-controlled asthma when assessing if the patient is at higher risk for asthma exacerbation, if a patient is YES, at higher risk, the treatment box below this heading showed All ages, start daily ICS but should read All ages, start daily ICS + PRN SABA.

The proper Figure 3 appears below.



*Higher risk if a patient had any of the following:

- 1) any history of a previous severe asthma exacerbation requiring:
 - systemic steroids,
 - ED visit, or
 - hospitalization
- 2) poorly-controlled asthma as per CTS criteria
- 3) overuse of short-acting beta-agonist (defined as use of more than two inhalers of SABA in a year)
- 4) current smoker

§ Based on patient preference—the decision to switch from PRN SABA to daily ICS + PRN SABA or PRN bud/form is for those that want better asthma control and to decrease their risk of exacerbation

☐ Dash boxes represent harm reduction strategy

SABA: short-acting beta-agonist; ICS: inhaled corticosteroids; bud/form: budesonide-formoterol in a single inhaler; ED: emergency department

This has been corrected in the article.